Xenon Pharmaceuticals Inc.

NASDAQ:XENE

35.18 (USD) • At close March 13, 2025
Bedrijfsnaam Xenon Pharmaceuticals Inc.
Symbool XENE
Munteenheid USD
Prijs 35.18
Beurswaarde 2,692,775,704
Dividendpercentage 0%
52-weken bereik 33.27 - 46
Industrie Biotechnology
Sector Healthcare
CEO Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
Website https://www.xenon-pharma.com

An error occurred while fetching data.

Over Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium

Vergelijkbare Aandelen

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

19.13 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

177.37 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.9 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

34.82 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

90.78 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

105.62 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

13.69 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

31.17 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

2.23 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)